Forging a New Standard of Care in TGCT: Intra-Articular Administration of AMB-05X

​

Tuesday, December 7th @ 1pm EST

​

The webinar featured presentations by tenosynovial giant cell tumor (TGCT) experts A.J. Hans Gelderblom, MD, PhD (Leiden University Medical Center) and Michiel van de Sande, MD, PhD (Leiden University Medical Center) who provided a background on TGCT and discuss the current treatment landscape as well as unmet medical need in treating TGCT patients.

​

AmMax Bio’s Chairman & Chief Executive Officer Larry Hsu, PhD, and Chief Medical Officer Michael Huang, MD, then provided a company update and discussed AmMax Bio’s AMB-05X, a human monoclonal antibody against the colony stimulating factor-1 receptor and administered intra-articularly, as a potential treatment of TGCT.

​

A live Q&A session followed the formal presentations. 

Speaker Biographies

A. J. (Hans) Gelderblom, MD, PhD

A.J. (Hans) Gelderblom, MD, PhD, is Head of the Department of Medical Oncology at the Leiden University Medical Center (LUMC) and Chair of the Comprehensive Cancer Network West in the Netherlands. Professor Gelderblom is an established expert in the treatment and management of bone and soft tissue tumors (including sarcomas and gastrointestinal stromal tumors [GIST]) and anti-cancer drug development and pharmacogenetics. He has served extensively on numerous scientific and advisory committees including the Dutch Organization of Medical Oncologists, Dutch Committee for Bone Tumours and the EORTC Soft Tissue and Bone Sarcoma Group. He is the author or co-author of over 250 papers on bone tumor, sarcoma, and GIST. Professor Gelderblom has served as a Principal Investigator on multiple clinical trials for tenosynovial giant cell tumor (TGCT) and is currently a key scientific advisor and Investigator to AmMax Bio’s TGCT clinical development program.

Michiel van de Sande, MD, PhD

Michiel van de Sande, MD, PhD, is Professor of Orthopedic Oncology at the Leiden University Medical Center (LUMC) and Pediatric Orthopedic Surgeon at the Princes Maxima Center for Pediatric Oncology in Utrecht, Netherlands. Professor van de Sande is a leading expert in the treatment of pediatric, adolescent, and adult patients with bone and soft tissue tumors and serves on the boards of multiple orthopedic/oncologic organizations including the Peadiatric Orthopedic working group of the Dutch Orthopedic Society, Orthopedic Oncology working group of the Dutch Orthopedic Society, Dutch Sarcoma Group, Co-chairman of the Tumor Study group EPOS, and EuroEwing Consortium Executive Group. He has published over 100 peer reviewed papers and book chapters and his research is funded by multiple scientific grants. Prof. van de Sande has participated in numerous tenosynovial giant cell tumor (TGCT) trials and is a key scientific advisor and Investigator to AmMax Bio’s TGCT clinical development program.